Recent years have witnessed an increasing interest in the study of the possible relationship of blood coagulation to intravascular thrombosis (1) (2) (3) (4) . In spite of numerous methods of investigation, a consistent means of demonstrating and defining a clotting abnormality in thromboembolic diseases has not emerged.
By retarding artificially the thromboplastin generation test (TGT) we have been able to show acceleration of thromboplastin generation in certain patients with intravascular thrombosis (5, 6) . Our experience to date indicates that 75 per cent of 52 patients who had arteriosclerosis obliterans with thrombosis demonstrated the acceleration, 50 per cent of 40 patients with "idiopathic" recurrent thrombophlebitis did likewise, but only 11 per cent of 35 patients who had arteriosclerosis obliterans without thrombosis exhibited acceleration of the TGT. Of several hundred "normal" plasmas, less than 1 per cent was abnormally rapid in the TGT. It became apparent that the cause of the rapid formation of thromboplastin in the blood of these patients was demonstrable only in the adsorbed plasma reagent of the TGT, not in the serum reagent. Since the adsorption of plasma removes plasma thromboplastin component (PTC or factor IX), stable factor (factor VII), and Stuart factor (factor X), as well as prothrombin, these substances are probably not directly involved in the clot acceleration. A number of other factors remains; these are considered in detail in the present report.
We wish to present evidence that the abnormal clot acceleration results from the presence of an * This investigation was supported in part by research grant H-5008(Ri) from the National Institutes of Health. excessive amount of coagulative activity which resides with the globulins in normal human plasma. We have designated this protein "thromboplastin generation accelerator," or simply "TGA," because its activity seems to lie in the thromboplastin generation phase of clotting. METHODS 1. One-stage prothrombin time of Quick (7) . This test, as modified locally (8) , gives a normal value of 17 to 19 seconds. For the determinations of "dilute prothrombin time," fresh plasma was diluted 1: 5 and 1: 10 with oxalated saline solution (1 part of 0.1 M sodium oxalate and 9 parts of 0.9 per cent sodium chloride), and the test was carried out in the usual manner. Normal values are 30 to 49 seconds for the 1: 5 dilution of plasma, and 56 to 67 seconds for the 1: 10 dilution.
2. Plasma clotting (recalcification) time (9) . The normal value is 90 to 110 seconds. (10) , modified by Duckert and co-workers (11) , with substitution of soybean phosphatides for platelets (12) . Normal values are the shortest clotting times, 8 to 11 seconds, occurring at 7 to 11 minutes of incubation. Retardation of the TGT (6) is carried out by diluting the plasmatic reagent 1: 50 with buffered saline [1 part of imidazole buffer (13) and 9 parts of 0.9 per cent sodium chloride] instead of our usual 1: 25 dilution [Duckert modification (11) ]. Normal values for the "retarded TGT" are the shortest clotting times, 13 to 16 seconds, occurring at 11 to 13 minutes of incubation. Since we have demonstrated excess TGA activity as well with soybean phosphatide as with platelets (5), the convenience of the former has led to its routine use. 4 . Electrophoresis of plasmatic factors (14) . The fresh plasma was first treated with barium sulfate (50 mg per ml, for 5 minutes at 240 C) to remove prothrombin and factors VII, IX and X; 0.15 ml was applied to strips of Whatman no. 2 filter paper, 4 cm wide. Electrophoresis was carried out in a cold room (40 C) for a period of 16 hours at a constant current of 0.6 ma per cm width of paper strips; the buffer used was sodium barbital-bar-bituric acid of pH 8.6 and 0.05 ionic strength. The various cut-paper fractions were eluted with 2.5 ml of buffered saline.
Thromboplastin generation test (TGT) of Biggs and Douglas
5. Precipitating with aninnoniun sulfate. At room temperature, 1 ml of fresh barium sulfate-adsorbed plasma, diluted to a total volume of 10 ml, was subjected to pro On the other hand, in the studies of the properties of TGA (electrophoretic mobility, precipitation, and heat stability) an attempt at more direct evaluation of TGA activity was made by the degree of augmentation of the generation of thromboplastin by normal plasma to which the fraction was added.
2. AHG-deficient plasma. Fresh plasma was obtained repeatedly from 2 severely hemophilic patients. These samples were cross checked with samples from 6 other hemophilic patients and all 8 exhibited the same defect, a lack of the antihemophilic globulin (AHG or factor VIII).
3. Aged normal plasma. Fresh normal plasma was heated to 37.50 C for 24 to 30 hours until the prothrombin time exceeded 60 seconds and the plasma clotting time exceeded 300 seconds. This plasma has been shown to be deficient in both factor V and AHG when tested against plasmas of parahemophilic and hemophilic patients.
All samples of plasma were oxalated by the addition of 0.5 ml of 0.1 M sodium oxalate to 4.5 ml of freshly drawn whole blood. We have shown in previous reports (5, 6 ) that acceleration of thromboplastin formation, when present, has always been restricted to the plasmatic reagent. Serum activity in the thromboplastin generation test in four representative cases in which accelerated thromboplastin formation was exhibited is shown in Table I . Serums in Patients 1, 2 and 3 were normal while the serum in Patient 4 was actually retarded because of the administration of coumarin drugs. The thromboplastin-generating activity of the plasmatic reagent in these patients ranged from two to five times normal. Because of this observation, it seemed unlikely that the serum factors could be responsible for the acceleration process.
RESULTS

Certain
Platelets likewise appear to bear no direct relationship to the phenomenon of plasma acceleration, since we have observed it in thrombocytopenic * Barium sulfate-adsorbed normal plasma and excess TGA plasma (Patient 1, Table IV) were electrophoresed on paper strips (see Methods); zones were eluted with buffered saline and each was then used as diluent for normal plasmatic reagent in the TGT instead of the usual saline diluent. Accelerator activity was found in -y and 8 zones, the former related to activity of AHG and factor V, the latter to TGA (see text).
t The 'yj and 72 zones were not clearly separable in this plasma and consequently were tested together. (Table IV) . It seems clear that TGA and AHG can be differentiated electrophoretically.
THROMIBOPLASTIN GENERATION ACCELERATOR
Eluates from the various fractions of both normal plasma and excess TGA plasma were tested for AHG activity (Table V) . In every instance the eluate from the Yi region decreased the recalcification time of AHG-deficient plasma, while eluates from the other fractions failed to influence significantly the clotting time of the hemophilic plasma. The apparent difference between our finding and that of Lewis, Walters, Didisheim and Merchant (15) may be technical, since this group used continuous flow electrophoresis. To exclude the effect of factor V, which usually travels with the yi plasma proteins (14) , the eluates of the /8 fraction of both the control plasma and the excess TGA plasma were heated to 56°C for 1 minute to inactivate completely any factor V that might have been present. These heated samples were then used as diluents for the plasmatic reagent in the TGT, as above. Neither the eluate from the control nor that from the excess TGA plasma showed any loss of activity after heating. It is assumed, therefore, that there was virtually no factor V activity in the /8 fractions, and in turn that the /8-globulin clotting activity was not attributable to factor V. In each electrophoretic test, fibrinogen was heavily concentrated at the point of application of the plasma to the paper strips in the y region, and far removed from the /8 fraction.
Hageman factor activity has been shown to reside in the Yi fraction (16) , and PTA activity in the 3,-y interspace (17) Effect of adsorbent chemicals. Each milliliter of plasma containing excess TGA was treated with barium sulfate (50 mg) for 5 minutes at 240 C, tricalcium phosphate (0.1 ml of a 0.2 M suspension) for 5 minutes at 240 C, or aluminum hydroxide (0.1 ml of a 6.1 per cent suspension) at 0°C for varying periods of time and then tested in the TGT. Normal plasma similarly treated was used as the control. The results are shown in Table VIII . Accelerated generation of thromboplastin was equally apparent after the barium sulfate and tricalcium phosphate treatment. On Prothrombin time of diluted plasma. Thus far, the evidence places TGA activity early in the clotting reaction (prothromboplastic step), because of acceleration in the TGT associated with normal prothrombin times. In order to assess any possible second-stage activity of TGA, prothrombin times, which are independent of the first stage, were determined on diluted specimens of a number of excess TGA plasmas (Table XII) . The results tend to exclude any second-stage activity comparable to that exhibited by factors V, VII and X. The indirect implication is that excess TGA activity is not the result of excess factor V. Determination of factor V activity in excess TGA plasma. Factor V activity in excess TGA plasma was assessed directly by noting the degree of correction of the prolonged prothrombin time of aged plasma on mixing the two plasmas. Three of the four studied showed no evidence of increased activity of factor V; in the fourth instance, there was modest acceleration as compared to control values (Table XIII) .
Because of this one apparent exception to an otherwise sharp differentiation of TGA and factor V, further discrimination was sought by way of the TGT (Table XIV) . Excess TGA plasma, which had approximately three times the normal thromboplastic activity in the TGT when measured in the conventional manner, was heated for 2 minutes at 56°C to inactivate factor V completely. When tested in the TGT this plasma still exhibited approximately the same degree of excess activity as before heating. (A constant source of factor V was added in the form of fresh AHGdeficient plasma.) Since increased thromboplastic activity persisted in the excess TGA plasma despite complete inactivation of its factor V content, it was assumed that factor V was not responsible for the increased activity of the unheated plasma in the TGT.
Effect of coumarin drug therapy. Many of the patients with thrombotic arterial and venous disease whose plasma showed the phenomenon of acceleration in the TGT were treated with one or another coumarin drug. In spite of lengthened prothrombin time and retardation of the serum activity in the TGT, their plasmas showed no reduction in excessive TGA activity. Results of the TGT of the plasma from one such patient on longterm anticoagulant therapy are illustrated in Figure 2 . This patient's prothrombin time was effectively prolonged by drug therapy, but the TGA activity of his plasma remained persistently elevated. We have also observed excess TGA in the plasma of certain patients with thrombotic disease in the presence of long-standing hepatic disease with demonstrable deficiencies of factors V, VII, X and prothrombin. * Factor V activity was removed from BaSO4-adsorbed excessTGA plasma by heating at 56°C for 2 minutes. Mixture of equal parts of this plasma and fresh unheated BaSO4-adsorbed AHG-deficient plasma (each diluted 1: 25) constituted plasmatic reagent for TGT. Final concentration of factor V was 1:50 (all from AHG-deficient plasma), and of AHG 1:50 (all from heated plasma). Normal plasma was similarly treated. TGA activity was not appreciably reduced by heating despite complete destruction of factor V.
t Normal plasma heated to 56°C for 2 minutes (1:25) plus fresh AHG-deficient plasma (1: 25). factors. This has led us to the conclusion that the rapid generation of thromboplastin in these patients cannot be satisfactorily explained on the basis of any currently identified blood-clotting factor. For clarification, we have applied to the newly recognized hypercoagulable activity the name "thromboplastin generation accelerator" (TGA), since its function is thereby described.
TGA was found to migrate electrophoretically with the p-globulins of plasma, and in this regard is like factor VII (14) and factor IX (19) . TGA, like AHG (factor VIII), labile factor (V), Hageman factor, PTA, and fibrinogen, was not adsorbed from plasma by barium sulfate. TGA did not survive clotting, and is therefore absent from serum, like antihemophilic globulin (factor VIII), labile factor (V), prothrombin and fibrinogen. On the basis of these simple experiments alone, there can be only a few well authenticated coagulation factors that might have the TGA activity.
Factor V. TGA is considerably more heat stable than factor V. Within 1 minute at 560 C, factor V activity in human plasma was completely dissipated, while TGA remained active for at least 15 minutes. When paper electrophoresis of fresh plasma was carried out, factor V activity could be demonstrated in the 8--y interspace (14) , while TGA activity was confined to the ,8 fraction. Prolonged contact with aluminum hydroxide decreased TGA activity in direct proportion to the length of exposure. In contrast, factor V activity remained unaffected even after 45 minutes of adsorption. When assays of factor V were carried out on plasmas containing excessive amounts of TGA, a moderate increase was found in only one of the four studied.
Antihemophilic globulin (AHG, factor VIII).
TGA was found to be somewhat more stable at 560 C than AHG, which was completely inactivated within 10 minutes. The stability of AHG, therefore, lies midway between that of factor V and that of TGA.
After electrophoresis of fresh barium sulfateadsorbed plasma, maximal AHG activity could be demonstrated in the y,-globulin fraction, but not in the /8-globulin zone of either normal plasma or plasma containing excess TGA. After precipitation with ammonium sulfate, AHG activity was confined to the 25 per cent saturation fraction (16, 17) would seem to distinguish them from TGA, since the thromboplas-tin-generating activity of serum from none of our patients with thromboembolism has been hyperactive. Furthermore, eluates of electrophoretically processed normal, barium sulfate-adsorbed serum, containing only PTA and Hageman factor as far as is known, did not enhance thromboplastin formation in a TGT of normal plasma and serum.
Both PTA, in the 18-y interspace, and Hageman factor, in the Yi zone, were effectively separated from TGA, in the 8 zone, by electrophoresis (16, 17) . Does TGA activity correspond to previously described blood coagulation factors? Increase in concentrations of factor VII (20) ) factor V (21), and AHG (22) in certain clinical states has been reported but does not seem pertinent in this discussion because of the significant differences between these clotting factors and TGA.
Wessler, Reimer and Deykin (4, 23) have described a serum activity capable of inducing thrombosis. They have entitled it serum thrombotic accelerator (STA). Since STA is present in serum and is readily adsorbed by barium sulfate, it cannot be reconciled with the properties of TGA.
The absence of TGA in serum, its resistance to barium sulfate adsorption, and its greater heat stability separate it from the prephase accelerator described by Fisch (24).
Waaler (25) has reported that there is an "activation product" resulting from the interaction of PTA and Hageman factor. Certain properties of activation product and TGA are similar: electrophoretic mobility, property of being unaffected by coumarin drugs, and susceptibility to ammonium sulfate precipitation. However, Waaler found activation product reduced four-fifths by heating plasma for 30 minutes at 370 C, whereas TGA is unaltered by this same treatment. Furthermore, Waaler states that "activation product was unstable when in plasma" and "in serum a great amount of activation product was found." Neither of these descriptions is compatible with our observations of TGA activity. We are unable to find in the literature any description of a coagulation activity like that of TGA.
Function of TGA. TGA appeared to influence primarily the rate of formation, and possibly the yield, of plasma thromboplastin. In the TGT, peak thromboplastic activity was reached in onehalf to two-thirds the time required by normal plasma. In addition, the activity of the thromboplastin produced was usually greater than that of the control, as evidenced by shorter clotting times in the substrate plasma. When I Key: + = depressed; 0 = no depression. activity was usually found to be associated with recent thrombosis. Before it is concluded that the excess TGA activity is simply the result of the thrombosis, it may be recalled that normal plasma exhibits a modest coagulative activity in the ,8-globulin zone indistinguishable from TGA.
Furthermore, in one patient studied serially for 3 years and in whom there was no further clinical evidence of thrombosis, excess TGA activity persisted unaltered. It should be stated that in one patient the excess TGA activity disappeared within 3 weeks.
Additional evidence that TGA is not prothrombin, or factor VII, IX or X, all of which tend to be depressed by coumarin-type therapy, is the fact that excess TGA activity is unaltered by such therapy. Since thrombi tend to disappear during anticoagulant therapy, the persistence of excess TGA activity again raises the question of any direct relationship between excessive TGA and thrombosis. The distinguishing properties of TGA are summarized in Table XV 
